



Systemic Therapy Update

INSIDE THIS ISSUE

- Benefit Drug List – Cladribine, Liposomal Doxorubicin
- Protocol Update – BRAVDOC, KSLDO, LYCDA, LYCHOP-R, LYCOPP, LYMIDVAP, LYRITUX
- Cancer Management Manual – Gynecology, Neuro-oncology, Skin Lymphoma
- Pre-Printed Order Update – CNTEMOZ, UGIFUIP, GIFUR2, GIRLAIFF, GOEP, KSVB, LUDOC, OSAJAP, OSAVAP
- Patient Education – Liposomal Doxorubicin (Caelyx®)
- Drug Update -- Chlorambucil reformulation, Erythropoietin (Eprex®) Pharmacare coverage
- Continuing Education – American Society of Clinical Oncology Annual Meeting

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BENEFIT DRUG LIST

The following new programs have been funded by the Provincial Systemic Therapy Program effective April 1, 2001:

Cladribine (Leustatin®) for hairy cell leukemia, moves from Class II to Class I on the Benefit Drug List.

Liposomal doxorubicin (Caelyx®) for Kaposi's Sarcoma.

Liposomal doxorubicin is now approved as a Class II drug on the benefit list. A Class II form must be completed and submitted to the Provincial Systemic Therapy Program before the drug will be dispensed

at a regional cancer centre or reimbursed to a community hospital.

Susan O'Reilly, MB, FRCPC
Provincial Systemic Program Leader

The current Benefit Drug List is available on the BCCA Communities Oncology Network website <http://bccancer.com>.

PROTOCOL UPDATE

Protocol codes for treatments requiring "Undesignated Indication" approval prior to use are prefixed with the letter **U**.

- **INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **BRAVDOC** revised (bilirubin deleted from tests, dose modifications and precautions): Palliative therapy for metastatic breast cancer using Docetaxel (Taxotere®)
- **KSLDO** new (replacing UKSLDO): Therapy of Kaposi's sarcoma using liposomal doxorubicin.
- **LYCDA** revised (cladribine status): Treatment of hairy cell leukemia with cladribine.
- **LYCHOP-R** revised (prednisone dose, hypersensitivity management): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab.
- **LYCOPP** revised (tests): Treatment of Hodgkin's disease using cyclophosphamide, vincristine, procarbazine and prednisone.
- **LYMIDVAP** deleted: Treatment of intra-ocular lymphoma with methotrexate, irradiation,

dexamethasone, vincristine, doxorubicin and procarbazine.

- **LYRITUX** revised (hypersensitivity management): Treatment of lymphoma with single agent rituximab.

Most protocols are available on the BCCA website <http://www.bccancer.bc.ca/ccp/>.

CANCER MANAGEMENT MANUAL

The **Gynecology, Neuro-oncology** and **Skin Lymphoma** sections have been revised.

The Cancer Management Manual is available on BCCA website <http://www.bccancer.bc.ca/cmm/>.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BCCA protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

- **CNTEMOZ:** Temozolomide as second line chemotherapy for recurrent malignant gliomas.
- **UGIFUIP:** Chemotherapy of pseudomyxoma peritonei using intraperitoneal mitomycin and fluorouracil.
- **GIFUR2:** Combined modality adjuvant therapy for high risk rectal carcinoma using fluorouracil, leucovorin, and radiation therapy.
- **GIRLAIFF:** Preoperative concurrent chemotherapy and radiotherapy and postoperative chemotherapy for locally-advanced (borderline resectable or unresectable) rectal adenocarcinoma.
- **GOEP:** Therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide.
- **KSVB:** Therapy for Kaposi's sarcoma with vinblastine-vincristine.
- **LUDOC:** Second-line treatment for advanced non-small cell lung cancer with docetaxel (Taxotere®).
- **OSAJAP** (pre-printed order entitled OSAJAP-VAP): Adjuvant therapy for osteosarcoma using doxorubicin and cisplatin.
- **OSAVAP** (pre-printed order entitled OSAJAP-

VAP): Therapy for advanced osteosarcoma using doxorubicin and cisplatin.

An index to the orders can be obtained by Fax-back.

PATIENT EDUCATION

Liposomal doxorubicin (Caelyx®) patient education handout is now available. Liposomal doxorubicin is currently indicated for the treatment of Kaposi's sarcoma (BCCA Protocol KSLDO).

DRUG UPDATE

Chlorambucil (Leukeran®, GlaxoSmithKline) 2 mg tablets were reformulated from a white film-coated tablet with room temperature storage to a brown, film-coated, round, biconvex tablet that requires refrigeration (2-8°C).

Erythropoietin (Eprex®) Pharmicare has recently reviewed the proposed coverage of erythropoietin for the treatment of anemia in cancer patients and decided that it would not be funded as a Pharmicare benefit drug. Based on the supporting literature for the proposal, Pharmicare felt that there was a lack of "substantive primary literature to support the therapeutic and economic case for erythropoietin in anemia of cancer." There are currently ongoing clinical trials in further investigating the use of erythropoietin for cancer-related anemia.

CONTINUING EDUCATION

The National Cancer Institute of Canada (NCIC) Spring Meeting The NCIC Clinical Trials Group Annual Meeting of Participants will be held in Montreal on 18-23 April, 2001.

The American Society of Clinical Oncology (ASCO) 37th Annual Meeting will be held in San Francisco, California, on 12-15 May, 2001. Information can be found on the ASCO website at www.ASCO.org.

The Oncology Nursing Society 26th Annual Congress will be held in San Diego on 17-20

May, 2001. The theme for this year will be "Pursuing Excellence in Challenging Times".

The BCCA Annual Cancer Conference will be held at the Wall Centre, Vancouver, on 22-24 November, 2001. The conference will include presentations for physicians, nurses, and pharmacists. Participants will be invited from the BCCA Community Cancer Centres. For more information about the conference, please contact Jack Chritchley at (604) 877 6183 or Barb Fiddler at (604) 877 6000 ext. 2744.

Editorial Review Board

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD
 Sandi Broughton, BA(Econ), MSc
 Jack Chritchley, MD
 Karen Janes, MSN
 Lynne Nakashima, PharmD
 David Noble, BSc, BLS

Gigi Concon (Secretary)

IN TOUCH	www.bccancer.bc.ca	Bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	Bfiddler@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	llundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	Gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	Gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	Francish@bccancer.bc.ca
Drug Information	Ext 3028	Robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	Dnoble@bccancer.bc.ca
Update Editor	Ext 2288	Mdelemos@bccancer.bc.ca
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	Toll-Free 1-(800)-523-2885
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 370-8228	Toll-Free 1-(800)-670-3322

BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247**OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247****PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES***I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:* E-mail (Word 6.0)

@

 Fax

()

Attn:

UPDATES Please Fax-Back information below:

<input type="checkbox"/> All items	
Patient Handouts:	
<input type="checkbox"/> Liposomal Doxorubicin	
Pre-Printed Orders:	
<input type="checkbox"/> CNTEMOZ	<input type="checkbox"/> UGIFUIP
<input type="checkbox"/> GIFUR2	<input type="checkbox"/> GIRLAIFF
<input type="checkbox"/> GOEP	<input type="checkbox"/> KSVB
<input type="checkbox"/> LUDOC	<input type="checkbox"/> OSAJAP
<input type="checkbox"/> OSAVAP	
<input type="checkbox"/> Index: Pre-Printed Orders	
Protocol Summaries:	
<input type="checkbox"/> BRAVDOC	<input type="checkbox"/> KSLDO
<input type="checkbox"/> LYCDA	<input type="checkbox"/> LYCHOP-R
<input type="checkbox"/> LYCOPP	<input type="checkbox"/> LYRITUX
<input type="checkbox"/> Index: Protocol Summaries (current month)	
Reimbursement	
<input type="checkbox"/> Benefit Drug List (01 April 2001)	
<input type="checkbox"/> Class 2 Form (01 April 2001)	
Systemic Therapy Update Index	
<input type="checkbox"/> Jan-Dec 2000	

REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Patient Handouts:	H:\everyone\systemic\chemo\Pt_Educ Liposomal Doxorubicin
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC
Index of Pre-Printed Orders	Index.doc
	CNTEMOZ
	UGIFUIP
	GIFUR2
	GIRLAIF
	GOEP
	KSVB
	LUDOC
	OSAJAP
	OSAVAP
Protocol Summaries	H:\everyone\systemic\chemo\Protocol\'tumour site'
	BRAVDOC
	KSLDO
	LYCDA
	LYCHOP-R
	LYCOPP
	LYRITUX
Index of Protocol Summaries	Index_NT or Index_W6
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List (01 April 2001)	BenefitList.doc
Class 2 Form (01 April 2001)	Class2.doc

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at <mailto:bulletin@bccancer.bc.ca>